0000899243-23-012905.txt : 20230512 0000899243-23-012905.hdr.sgml : 20230512 20230512200922 ACCESSION NUMBER: 0000899243-23-012905 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230511 FILED AS OF DATE: 20230512 DATE AS OF CHANGE: 20230512 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sullivan Lynne Marie CENTRAL INDEX KEY: 0001727640 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38470 FILM NUMBER: 23917926 MAIL ADDRESS: STREET 1: C/O SOLID BIOSCIENCES, LLC STREET 2: 141 PORTLAND STREET, FIFTH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Unity Biotechnology, Inc. CENTRAL INDEX KEY: 0001463361 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 264726035 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 285 EAST GRAND AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (650) 416-1192 MAIL ADDRESS: STREET 1: 285 EAST GRAND AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: Cenexys, Inc. DATE OF NAME CHANGE: 20130703 FORMER COMPANY: FORMER CONFORMED NAME: Forge Inc DATE OF NAME CHANGE: 20090504 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-05-11 0 0001463361 Unity Biotechnology, Inc. UBX 0001727640 Sullivan Lynne Marie C/O UNITY BIOTECHNOLOGY, INC. 285 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 0 1 0 0 See Remarks 0 Stock Option (Right to Buy) 2.77 2023-05-11 4 A 0 40000 2.77 A 2033-05-11 Common Stock 40000 40000 D Stock Option (Right to Buy) 99.60 2023-05-11 4 D 0 24000 0.00 D 2030-08-01 Common Stock 24000 0 D Stock Option (Right to Buy) 2.77 2023-05-11 4 A 0 24000 0.00 A 2030-08-01 Common Stock 24000 24000 D Stock Option (Right to Buy) 41.80 2023-05-11 4 D 0 12333 0.00 D 2031-06-24 Common Stock 12333 0 D Stock Option (Right to Buy) 2.77 2023-05-11 4 A 0 12333 0.00 A 2031-06-24 Common Stock 12333 12333 D Stock Option (Right to Buy) 10.60 2023-05-11 4 D 0 20000 0.00 D 2032-02-09 Common Stock 20000 0 D Stock Option (Right to Buy) 2.77 2023-05-11 4 A 0 20000 0.00 A 2032-02-09 Common Stock 20000 20000 D The underlying shares vest and become exercisable pursuant to the following schedule: One-eighth of the shares subject to the option vest in successive, equal quarterly installments starting on August 11, 2023, subject to the Reporting Person's continued service to Issuer through the applicable vesting date. The underlying shares vest and become exercisable pursuant to the following schedule: Twenty Five Percent (25%) of the shares subject to the option vested on August 1, 2021 (the "Vesting Commencement Date"), and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. On May 11, 2023, the option originally granted to the Reporting Person on August 1, 2020 was amended to reduce the exercise price to $2.77 per share. All of the other terms of the option remain unchanged. Shares subject to the stock option vest and become exercisable in successive, equal monthly installments over a 48-month period commencing on June 24, 2021 (the "Vesting Commencement Date"), so that 100% of the shares become fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. On May 11, 2023, the option originally granted to the Reporting Person on June 24, 2021 was amended to reduce the exercise price to $2.77 per share. All of the other terms of the option remain unchanged. The underlying shares vest and become exercisable pursuant to the following schedule: One Third of the shares subject to the option vest on February 9, 2023 (the "Vesting Commencement Date"), and the remaining shares subject to the option vest in 24 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. On May 11, 2023, the option originally granted to the Reporting Person on February 9, 2022 was amended to reduce the exercise price to $2.77 per share. All of the other terms of the option remain unchanged. CFO and Head of Corporate Development /s/ Alexander Nguyen, Attorney-in-Fact for Lynne Marie Sullivan 2023-05-12